Skip to main content

Table 2 Key efficacy outcomes at week 16 in the CRP−/MRI+ subgroup by screening SIJ MRI score

From: Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT

Endpoints, % responders (n/M) Screening SIJ MRI score Pooled secukinumab 150 mg Placebo
ASAS40 < 2 31.7 (26/82) 30.0 (12/40)
≥ 2 42.5 (31/73) 32.5 (13/40)
ASAS PR < 2 14.6 (12/82) 7.5 (3/40)
≥ 2 24.7§ (18/73) 7.5 (3/40)
ASDAS-CRP ID < 2 17.1 (14/82) 15.0 (6/40)
≥ 2 30.1 (22/73) 12.5 (5/40)
  1. NRI data presented for all variables
  2. The total number of patients in the screening MRI score of < 2 subgroup was 82 (pooled secukinumab 150 mg) and 40 (placebo) and in the screening MRI score ≥ 2 subgroup was 73 (pooled secukinumab 150 mg) and 40 (placebo)
  3. ASAS Assessment of SpondyloArthritis international Society, ASDAS Ankylosing Spondylitis Disease Activity Score, CRP C-reactive protein, ID inactive disease, M number of evaluable patients, MRI magnetic resonance imaging, NRI non-responder imputation, PR partial remission, SIJ sacroiliac joint
  4. §P < 0.01, P < 0.05 versus placebo